Chemicals
Butyl paraben, cremophor EL, 1,2-propanediol, β-glucuronidase (type B-1 from bovine liver, containing 1 240 000 units/g of β-glucuronidase) and sulfatase (type H-1 from Helix pomatia, containing 14 000 units/g of sulfatase and 498 800 units/g of β-glucuronidase) were purchased from Sigma. L(+)-ascorbic acid and ortho-phosphoric acid were obtained from Riedel-deHaën AG. Acetonitrile, ethyl acetate, and methanol were obtained from J. T. Baker, Inc. Magnolol was obtained from Wako (purity 99 %). nHexane was purchased from ALPS Chemical, Ltd. Sodium acetate was obtained from Kohusan Chemical Works, Ltd. Milli-Q plus water (Millipore) was used for all processes.
Instrumentation
The high-performance liquid chromatography (HPLC) apparatus included a pump (LC-6AD; Shimadzu), an UV spectrophotometric detector (SPD-6A; Shimadzu), a chromatopac (C-R6A; Shimadzu), and an autosampler (Series 200; Perkin Elmer). RP-18e column (LiChrospher, 250 × 4.0 mm) was used with a prefilter (Isolation Technologies).
Animals and drug administration
All animal experiments adhered to "The Guidebook for the Care and Use of Laboratory Animals" published by the Chinese Society of Animal Science, Taiwan, ROC). The animal protocol (95-159-D) was approved by the Institutional Animal Care and Use Committee of the China Medical University, Taiwan. Male Sprague-Dawley rats (350-450 g) were supplied by BioLASCO and kept at least 2 weeks under a conditioned environment with free access to food and water. Before the experiment, the rats were fasted overnight but drinking water was allowed ad libitum. Food was supplied 3 h after M dosing. M solution was prepared by dissolving M in a vehicle composed of equal weight of 1,2-propanediol and cremophor EL to afford a concentration of 20 mg/mL. For the pharmacokinetic study, five rats were given an intravenous bolus of M at 20 mg/kg; in addition, rats were orally given a single dose (n = 5) and seven doses (n = 6) of M at 50 mg/kg by gastric gavage. For the tissue distribution studies, three rats were orally given 50 mg/kg of M thrice daily for seven doses prior to the sacrifice for tissue collection.
Blood specimen collection
In the pharmacokinetic study, blood samples (0.7 mL) were collected via cardiac puncture at 5, 10, 15, 20, 30, 45, 60, 120, 240 , and 480 min after intravenous dosing and at 5, 10, 15, 30, 60, 120, 240, and 480 min after oral administration. In the tissue distribution study, a blood sample was withdrawn at 30 min after the 7th dose of oral M. The sera were collected by centrifuging at 10 000 g for 15 min to obtain the supernatants and stored at −30°C until analysis.
Tissue collection and pretreatment
At 30 min after the 7th dose of M, rats were sacrificed by inhaling CO 2 and systemically perfused with cool normal saline. Then, the organs including the brain, liver, lung, heart, and kidney were removed, blotted dry with filter paper and accurately weighed. The tissues were homogenized with normal saline (700 mg/mL), and the homogenates were stored at −30°C until analysis.
Quantitation of M in serum and tissue homogenates
To determine the serum concentration of M, 100 µL of serum was added to 100 µL of acetate buffer (pH 5.0), 50 µL of ascorbic acid (200 mg/mL), and 50 µL of 0.1 N HCl, then partitioned with 300 µL of ethyl acetate containing 5.0 µg/mL of butyl paraben as the internal standard. After centrifuging at 10 000 g for 15 min, the supernatant was dried under nitrogen gas and reconstituted with an appropriate volume of acetonitrile before HPLC analysis. For the determination of M concentration in various tissue homogenates, 500 µL of homogenate was added to 100 µL of acetate buffer (pH 5.0), 100 µL of ascorbic acid (200 mg/mL), and 20 µL of 0.1 N HCl, then partitioned with 700 µL of ethyl acetate containing 0.5 µg/mL of butyl paraben as the internal standard. The later procedures followed that of serum samples. For HPLC analysis of both serum and tissues, the mobile phase used was acetonitrile/ 0.1 % ortho-phosphoric acid (48 : 52), and it was run isocratically. The flow rate was 1.0 mL/min with the detection wavelength set at 290 nm.
Quantitation of M S/G in serum and tissue homogenates
For serum analysis, 100 µL of serum, 100 µL of sulfatase solution (containing 10 units of sulfatase and 210 units of β-glucuronidase in pH 5.0 acetate buffer), and 50 µL of ascorbic acid (200 mg/mL) were added into a light protected test tube and incubated at 37°C for 120 min, which had been determined by a preliminary study for reaching optimum hydrolysis. For tissue analysis, 500 µL of various tissue homogenates, 100 µL of sulfatase solution (containing 10 units of sulfatase and 210 units of β-glucuronidase in pH 5.0 acetate buffer), and 100 µL of ascorbic acid (200 mg/mL) were added into a light protected tube and incubated at 37°C for 120 min, which had been determined by a preliminary study. The concentration of M S/G was calculated from the total M concentration after hydrolysis minus that before hydrolysis. The later procedures followed that described above for the quantitation of M in tissue.
Quantitation of MG in serum and tissue homogenates
For the analysis of serum, 100 µL of serum, 100 µL of β-glucuronidase solution (containing 100 units of β-glucuronidase in pH 5.0 acetate buffer), and 50 µL of ascorbic acid (200 mg/mL) were added into a light protected test tube and incubated at 37°C for 60 min, which had been determined by a preliminary study for reaching optimum hydrolysis. For tissue analysis, 500 µL of homogenates, 100 µL of β-glucuronidase solution (containing 100 units of β-glucuronidase in pH 5.0 acetate buffer), and 100 µL of ascorbic acid (200 mg/mL) were added into a light protected tube and incubated at 37°C for 120 min, which had been determined by a preliminary study. The concentration of MG was calculated from the total M concentration after hydrolysis minus that before hydrolysis. The later procedures followed that described above for the quantitation of M in tissue.
Validation of assay methods
The precision and accuracy of the assay methods were evaluated by intraday and interday analysis of triplicates at concentrations of 0.5, 3.1, and 25.0 µg/mL of M in serum, and 0.16, 0.63, and 2.5 µg/mL of M in various tissue homogenates over a period of three days. Lower limit of quantitation (LLOQ) represents the lowest concentration of analyte in a sample that can be determined with acceptable precision and accuracy, whereas limit of detection (LOD) represents the lowest concentration of analyte in a sample that can be detected (with S/N > 3).
Calculation of pharmacokinetic parameters and statistical analysis
Pharmacokinetic parameters were calculated by a noncompartment model of WinNonlin (version 1.1 SCI software; Statistical Consulting, Inc). The peak serum concentration (C max ) and the time to peak concentration (T max ) were calculated based on experimental measurements. The areas under the curves (AUC 0-t ) from time zero to last were calculated by the trapezoidal rule. The oral absolute bioavailability (F) of M was calculated by the following equation:
One-way ANOVA with Scheffeʼs test was used for statistical comparisons.
Supporting information
The method of magnolol isolation and validation of the analytical methods are available as Supporting Information.
Results

!
The calibration curve of M in the range of 0.13-50.0 µg/mL in serum showed good linearity (r > 0.99). The precision evaluation showed that all coefficients of variation were below 8.6%, and the accuracy analysis demonstrated that the relative errors to the true concentrations were below 8.0 %. The recoveries of M from serum were 86.7-96.5 % at 0.5, 5.0, and 20.0 µg/mL. The LLOQ and LOD of M in serum were 0.13 and 0.06 µg/mL, respectively. For tissue analyses, good linearities (r > 0.99) were obtained in the ranges of 0.16-2.5 µg/mL of M in the brain homogenate and 0.08-2.5 µg/mL in the homogenates of the liver, kidney, lung, and heart. The precision evaluation showed that all coefficients of variation were below 17.2 %, and the accuracy analysis determined that the relative errors to the true concentrations were below 12.5 %. The recoveries of M from the brain, liver, lung, heart, and kidney were 106.4-108. in the blood rapidly after oral dosing, and the serum profile of M was much lower than that of M S/G. The pharmacokinetic parameters are listed in l " Table 1 . After single-dose administration, the C max and AUC 0-480 of M S/G were significantly higher than those of M by 180% and 350 %, respectively. After the 7th dose, the C max and AUC 0-480 of M S/G were significantly higher than those of M by 606% and 584 %, respectively. Comparison of the C max of M between two treatments showed that single-dose administration resulted in a higher C max of M than the 7th dose by 73 %. On the contrary, the AUC 0-480 of M and M S/G after the 7th dose was significantly higher than those after a single dose by 104% and 183 %, respectively. The distribution of M, MG, and M S/G in various tissues after the 7th dose of M are shown in l " Fig. 4 . Contrary to the finding in serum, the major molecule in each organ was M rather than M S/G. The concentration of M in the liver was the highest and those in the kidney, brain, lung, and heart were much lower and comparable. All organs assayed contained higher concentrations of M than serum. The liver also contained the highest concentration of M S/G than other organs and even higher than serum, whereas only traces of M S/G were present in the lung, heart, brain, and kidney. The concentrations of M S/G were comparable with those of MG in these organs.
Discussion
!
In this study, we established and validated the quantitation method of M in serum and various tissue homogenates. The analytical precision and accuracy as well as recoveries were satisfactory. Owing to the unavailability of authentic standards of MG and magnolol sulfates (MS), β-glucuronidase and sulfatase were used to hydrolyze them, and then the released M was determined. The commercial sulfatase (type H-1) used in this study contained not only sulfatase but also a considerable amount of β-glucuronidase. Therefore, both sulfates and glucuronides were hydrolyzed when treated with sulfatase. Through comparing the released amounts of M between treatments with sulfatase/glucuronidase and β-glucuronidase, the concentration of MS could be estimated. A previous study reported the intravenous pharmacokinetics of M in rats, but only M had been quantitated [17] . In this study, we determined not only M but also M S/G. After an intravenous bolus, the serum profiles revealed that M was instantaneously metabolized by the liver into M S/G [18, 19] . Comparable AUC 0-480 between MG and M S/G, shown in l " Table 1 , indicated that the major conjugates in the circulation were MG whereas MS were negligible. The AUC 0-480 of M and MG was comparable, implying that they were equally exposed to the vascular system. When rats were orally administered with a single dose of M (50 mg/kg), both M and M S/G were found in the serum. l " Fig. 3 A revealed that M was rapidly absorbed and metabolized extensively by conjugation reactions like other polyphenols [18] [19] [20] [21] .
The presence of a free form in serum is not quite usual among polyphenols, which were known to be exclusively metabolized during the first pass [22, 23] . The comparable AUC 0-t between MG and M S/G indicated that MG were the major conjugates.
The significantly higher C max and AUC 0-t of MG than M revealed that the major molecules in serum were MG. This finding was consistent with a previous study reporting that bile contained 48-49 % of MG, 7 % of M, and 2% of MS after oral administration of M to rats [16] . The absolute bioavailability of M was calculated as being only 4 % which is similar to a previous study [24] . The low bioavailability might be partly explained by the high metabolism during the passage through the gut and liver [16] . If the AUC 0-480 of M S/G was added into the calculation, the oral bioavailability of M became 17.8 %. The poor bioavailability of M might be accounted for by its low solubility in gastrointestinal juice. In order to understand the steady-state pharmacokinetics of M, rats were orally given 50 mg/kg of M three times a day for 7 doses. l " Fig. 3 B depicting the serum profiles after the 7th dose revealed an apparently different pattern from that in l " Fig. 3 A.
The concentrations of M appeared at a lower and stable level whereas those of M S/G were much higher and with three peaks at 15, 60, and 240 min, which was in agreement with a previous study suggesting enterohepatic circulation of M conjugates [16] . The AUC 0-t of M S/G was higher than that of MG by 58 % although statistical significance was not reached (p = 0.08). In contrast to single-dose pharmacokinetics, we speculate that after repeated dosing, the glucuronidation of M might have been saturated and sulfation took a turn as an alternative metabolic pathway. In addition, serum specimens had been collected right before the 4th and 7th dose and quantitated. The concentrations of M S/G were 1.5 ± 0.3 and 3.4 ± 0.4 nmol/mL, respectively, whereas M was not detected. This evidence indicated that there was accumulation of M S/G but not M. For tissue distribution analysis, in order to prevent the interference of residual blood, rats were systemically perfused with cool normal saline before organ collection. The results show that M was the major form in various organs, which was opposite to the finding in serum in which M S/G were predominant. We speculate that M S/G in the blood were hydrolyzed by β-glucuronidase or sulfatase in the surface cells of various organs and then permeated into the organs [25] [26] [27] . Among the assayed organs, comparable concentrations of M S/G and MG indicated that MG were the major conjugated metabolites. The liver contained the highest concentration of M and M S/G, which was in good agreement with the finding of a previous study using [ring- 14 C] labeled M [16] . Nevertheless, the previous study was not able to distinguish M from M S/G. In contrast, our study found that both M and MG were present in the liver, and M was the major form. Despite the anti-hepatoma activity of M demonstrated by in vitro studies [6, 8] , the reported effective concentration (100 nmol/mL) may not be achievable in vivo based on the estimation from our pharmacokinetic findings. Besides, the liver also contained the highest concentration of MG among the studied organs. In the past, the conjugated metabolites were thought to be inactive and eliminated as the final products of drugs from the body. However, the conjugated metabolites of polyphenols increasingly attracted the interest of researchers. For instance, the paregoric effect of morphine 6-glucuronide was found to be more potent than the one of morphine, and a clinical trial of morphine 6-glucuronide is ongoing [28, 29] . In addition, the glucuronides of morin and quercetin showed potential bioactivities [30] [31] [32] [33] . Till now, most in vitro bioactivity studies investigated M only, rather than M S/G [6, 7, 9, 11] . Given that abundant M S/G were present in the bloodstream and liver, the bioactivities of M S/G in the vascular system and liver warrant future studies. In summary, M S/G were the major forms in circulation, whereas M was predominant in the liver, kidney, brain, lung, and heart after oral administration of M. Among the tissues, the liver contained the highest concentrations of M and MG.
